Mediamedic/LinkedIn
Oct 4, 2025, 12:30
Professor Xue Feng: AAV Gene Therapy Transforming Hemophilia B Treatment in China
Mediamedic shared a post on LinkedIn:
“ISEH 2025 | Professor Xue Feng: AAV Gene Therapy Transforming Hemophilia B Treatment in China
At the 54th Annual Scientific Meeting of ISEH in Kumamoto, Japan, Professor Xue Feng (Institute of Hematology & Blood Diseases Hospital, CAMS) presented her work on AAV vector–based gene therapy expressing Factor IX Padua for Hemophilia B.
In an exclusive interview with Oncology Frontier – Hematology Frontier, she shared the science behind this innovative approach, its clinical potential, and the future of gene therapy development in China.”
Stay updated with Hemostasis Today.
-
Jan 10, 2026, 08:56Shivanand Kumatagi Reflects on His Visit to Rela Hospital
-
Jan 10, 2026, 08:48Mitchell Elkind: Why Is The American Heart Association Holding a Brain Health Symposium?
-
Jan 10, 2026, 08:41Fiona Robinson Invites You to NBDF Webinar on Research Grants
-
Jan 10, 2026, 08:30Melissa Korn Takes Front Page Award for Her WSJ Piece on Experiencing a Pulmonary Embolism
-
Jan 10, 2026, 08:20Aymar Akilimali on Malaria in the Democratic Republic of Congo
-
Jan 9, 2026, 12:17Louise St Germain Bannon Invites You to Self-Nominate for the ISTH Council
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management